FIELD: pharmaceutical industry.
SUBSTANCE: peptide compound is proposed, consisting of an amino acid sequence WFGFTGSL or KLNRRWWFGFTGSL, having a capability of inducing apoptosis in a tumor cell, which can be used as a therapeutic agent for the treatment of diseases related to impaired expression of cathepsin S and/or proteins of BCL-2 family. The invention also relates to the use of a peptide compound for induction of apoptosis in a tumor cell, for preparation of a drug causing induction of apoptosis in a tumor cell, as well as to a pharmaceutical composition for induction of apoptosis in a tumor cell, containing the specified peptide compound and a pharmaceutically acceptable carrier.
EFFECT: obtainment of peptide compounds for induction of apoptosis in a tumor cell.
4 cl, 8 dwg, 7 ex
| Title | Year | Author | Number |
|---|---|---|---|
| APPLICATION OF PEPTIDE COMPOUND FOR APOPTOSIS INDUCTION IN A TUMOR CELL | 2022 |
|
RU2796104C1 |
| SPECIFIC PEPTIDE INHIBITORS OF CYSTEINE CATHEPSINS | 2020 |
|
RU2752531C1 |
| METHOD FOR DETERMINING AMOUNT OF Bel-2 AND Bax PROTEINS IN VASCULAR WALL IN PATIENTS WITH OBLITERATING ATHEROSCLEROSIS OF ARTERIES OF LOWER EXTREMITIES | 2020 |
|
RU2751822C1 |
| PREDICTION OF RESPONSE TO ALVICIDIB BY ANALYSIS OF MITOCHONDRION PROFILE | 2016 |
|
RU2717829C2 |
| AGENT AND METHOD FOR APOPTOSIS INDUCTION IN CANCER CELLS | 2012 |
|
RU2488408C1 |
| PHARMACEUTICAL COMBINATIONS FOR TREATING A MALIGNANT TUMOR | 2017 |
|
RU2726367C2 |
| Bcl-2 PROTEINS, FRAGMENTS THEREOF, AND APPLICATION THEREOF IN PATIENTS WITH MALIGNANT TUMOUR | 2004 |
|
RU2367468C2 |
| PEPTIDE SUBSTRATES OF CYSTEINE PEPTIDES OF FAMILY OF PAPAIN | 2018 |
|
RU2717689C2 |
| PROAPOPTOSIS PROTEINS-CONTAINING THERAPEUTIC AGENTS | 2002 |
|
RU2319709C2 |
| METHOD OF DETECTING PRESENCE OF SYSTEMIC REACTION OF CONNECTIVE TISSUE, CONDITIONED BY DEVELOPMENT OF SYNDROME OF COMBINED DYSTROPHIC-DEGENERATIVE CHANGES OF MESENCHYMAL DERIVATIVES IN CASE OF LOCAL CHRONIC INFLAMMATORY PROCESS | 2012 |
|
RU2493777C1 |
